1. Scrip

Dr. Califf Returns To US FDA: What To Do First?

 
• By Derrick Gingery

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

Robert Califf
Robert Califf was confirmed by the Senate as FDA commissioner on 15 February. • Source: Alamy

Robert Califf, who squeaked through the US Senate to become the first person confirmed twice as Food and Drug Administration commissioner, will return with urgent items already on his agenda, including some pushed to the top to smooth his path to the job.

Califf received only 50 votes in favor of confirmation on 15 February, which was the lowest total a nominee to head the FDA has received. Scott Gottlieb previously had received...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.